Pharmaceutical formulations
Grant
US12594243B2
Kind: B2
Apr 07, 2026
Assignee
THERACOSBIO, LLC
Inventors
Feng Wang, Ankit Shrivastava, Rina Shah, Brian Seed, Vinay Patil, Michael J. Hadd, Fuxia Dong, Vipan Dhall, Chunfeng Dai, Joseph Ho-Lun Chau, Qiuhua Cai
Abstract
The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, Cmax, while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.
CPC Classifications
A61K 9/2013
A61K 9/006
A61K 9/2054
A61K 9/284
A61K 31/70
Filing Date
2023-11-03
Application No.
18501714
Claims
7